{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:56:45Z","timestamp":1783076205737,"version":"3.54.6"},"reference-count":47,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T00:00:00Z","timestamp":1298419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Alogliptin is a potent and highly selective dipeptidyl peptidase\u20104 (DPP\u20104) inhibitor. The aim of this study was to determine its effects on glucose control and pancreas islet function and to identify the underlying molecular mechanisms after chronic administration, in a non\u2010genetic mouse model of type 2 diabetes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Alogliptin (5, 15 and 45 mg\/kg) was orally administered to high fat diet\/streptozotocin (HFD\/STZ) diabetic mice daily for 10 weeks. Postprandial and 6\u2010h fasting blood glucose levels, blood A1C level, oral glucose tolerance and pancreas insulin content were measured during or after the treatment period. Alogliptin plasma concentration was determined by an LC\/MS\/MS method. Islet morphology and architectural changes were evaluated with immunohistochemical analysis. Islet endocrine secretion ability was assessed by measuring insulin release from isolated islets which were challenged with 16 mM glucose and 30 mM potassium chloride, respectively. Gene expression profiles of the pancreas were analysed using the mouse diabetes RT\n                    <jats:sup>2<\/jats:sup>\n                    Profiler PCR array which contains 84 genes related to the onset, development and progression of diabetes.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Alogliptin showed dose\u2010dependent reduction of postprandial and fasting blood glucose levels and blood A1C levels. Glucose clearance ability and pancreas insulin content were both increased. Alogliptin significantly restored the\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010cell mass and islet morphology, thus preserving islet function of insulin secretion. Expression of 10 genes including\n                    <jats:italic>Ins1<\/jats:italic>\n                    was significantly changed in the pancreas of diabetic mice. Chronic alogliptin treatment completely or partially reversed the abnormalities in gene expression.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Chronic treatment of alogliptin improved glucose control and facilitated restoration of islet architecture and function in HFD\/STZ diabetic mice. The gene expression profiles suggest that the underlying molecular mechanisms of\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010cell protection by alogliptin may involve alleviating endoplasmic reticulum burden and mitochondria oxidative stress, increasing\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010cell differentiation and proliferation, enhancing islet architecture remodelling and preserving islet function.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2010.01354.x","type":"journal-article","created":{"date-parts":[[2010,12,9]],"date-time":"2010-12-09T07:53:22Z","timestamp":1291881202000},"page":"337-347","source":"Crossref","is-referenced-by-count":50,"title":["Effects of chronic administration of alogliptin on the development of diabetes and\n                    <i>\u03b2<\/i>\n                    \u2010cell function in high fat diet\/streptozotocin diabetic mice"],"prefix":"10.1111","volume":"13","author":[{"given":"X.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,23]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105685"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2007.05.004"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/10.1210\/er.2006-0038"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29069"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-3581(03)00520-8"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2005.01566.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmec.2004.09.011"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1047"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X182068"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.06.002"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.12.2270"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01238.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0031"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2006.08.003"},{"key":"e_1_2_7_17_2","first-page":"113","article-title":"Incretin mimetics and DPP\u20104 inhibitors: new approach to treatment of type 2 diabetes mellitus.","volume":"18","author":"Siddiqui NI.","year":"2009","journal-title":"Mymensingh Med J"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/713609354"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02427280"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.pt2.55S"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm070104l"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.04.047"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2337\/diab.30.12.1045","article-title":"A new genetically obese\u2010hyperglycemic rat (Wistar fatty).","volume":"30","author":"Ikeda H","year":"1981","journal-title":"Diabetes"},{"key":"e_1_2_7_24_2","first-page":"171","volume-title":"Lessons from Animal Diabetes. The Tokyo Workshop 1990.","author":"Matsuo T"},{"key":"e_1_2_7_25_2","first-page":"A465.","article-title":"Effects of SYR\u2010322, a novel inhibitor of dipeptidyl peptidase\u2010IV alone or in combination with pioglitazone in obese and non\u2010obese type 2 diabetes model rats and mice.","volume":"55","author":"Takeuchi K","year":"2006","journal-title":"Diabetes"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.04.018"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90027-0"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-4-199908170-00008"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/db05-1602"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.09.027"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.16.1.35"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118649"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.02.092"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7750"},{"key":"e_1_2_7_35_2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2337\/diab.44.11.1285","article-title":"Phosphofructokinase isozymes in pancreatic islets and clonal \u03b2\u2010cells (INS\u2010l).","volume":"44","author":"Yaney GC","year":"1995","journal-title":"Diabetes"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2003-1602"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00466.2002"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.18.2323"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10735-004-2633-4"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1996.271.4.E725"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.5.3091"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/82489"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2010.02.008"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.20443"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009705200"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.09.009"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0260155"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(07)70190-8"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2010.01354.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2010.01354.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:10:12Z","timestamp":1761887412000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2010.01354.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,23]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1463-1326.2010.01354.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01354.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,23]]}}}